Table 5.
Comparison of the diagnostic utility of single CA15-3 and CEA assays and selected combinations of these markers with other parameters in the diagnosis of BC patients
| Parameter | SN [%] | SP [%] | AUC | References |
|---|---|---|---|---|
| CEA | 7.18 | 98.85 | – | Chen et al. (2020b) |
| CA15-3 | 7.47 | 99.23 | – | |
| CA125 | 4.89 | 95.02 | – | |
| CEA+CA15-3 | 12.93 | 98.08 | – | |
| CEA+CA125+CA15-3 | 16.95 | 93.10 | – | |
| TAP+CEA+CA15-3 | 17.82 | 97.70 | – | |
| TAP+CEA+CA125+CA15-3 | 21.84 | 92.72 | – | |
| CEA | 23.94 | 67.44 | 0.679 | Luo et al. (2022) |
| CA15-3 | 15.00 | 96.43 | 0.727 | |
| CA125 | 16.54 | 93.57 | 0.695 | |
| AFP+CEA+CA15-3 | 83.46 | 74.29 | 0.913 | |
| CEA+CA125+CA19-9 | 83.08 | 73.57 | 0.922 | |
| AFP+CA15-3+CA125 (accuracy 80.25%) | 82.31 | 77.14 | 0.905 | |
| Nipple discharge (ND) | Wang et al. (2014) | |||
| CEA | 69.8 | 86.0 | 0.779 | |
| CA15-3 | 74.4 | 82.4 | 0.784 | |
| CA125 | 72.1 | 83.8 | 0.780 | |
| Serum | ||||
| CEA | 53.5 | 89.0 | 0.712 | |
| CA15-3 | 60.5 | 91.9 | 0.762 | |
| CA125 | 55.8 | 90.4 | 0.732 | |
| (ND+serum) CEA+CA15-3+CA125+TSGF | 97.7 | 75.0 | 0.863 | |
| CEA | 81.8 | 69.4 | 0.799 | Zou et al. (2022) |
| NLR+CEA+CA19-9 | 76.5 | 88.9 | 0.886 | |
| CA15-3 | 58 | - | 0.634 | Zuo et al. (2016) |
| CA15-3+LGALS3+PHB2+MUC1+GK2 | 87 | 76 | 0.872 | |
| CA15-3 | 69.1 | 89.4 | 0.792 | Dong et al. (2013) |
| FTH1+CA15-3 | 85.1 | 92.7 | 0.834 | |
| hnRNPF+CA15-3 | 87.4 | 91.0 | 0.862 | |
| FTH1+hnRNPF+CA15-3 | 89.3 | 93.8 | 0.931 | |
| early-stage BC | Liu et al. (2018) | |||
| CA15-3 | 52.3 | 73.3 | 0.607 | |
| PD-1+IL-10+IL-2Rα+CA15-3 | 93.3 | 61.4 | 0.811 | |
| advanced BC | ||||
| CA15-3 | 65.2 | 100 | 0.791 | |
| PD-1+IL-10+CA15-3 | 93.3 | 78.3 | 0.896 | |
| BC (total) | ||||
| CA15-3 | 64.4 | 73.3 | 0.707 | |
| PD-1+IL-10+IL-2Rα+CA15-3 | 93.3 | 72.4 | 0.862 | |
| CA15-3 | 58.33 | 95.00 | 0.7573 | Zajkowska et al. (2019) |
| VEGF-C+CA15-3 | 86.67 | 70.00 | 0.8476 | |